Firstly, since the study detected the quantitative correlation between FGF21 and hepatic fat content in a specific group of participants with abnormal glucose metabolism and B ultrasound-diagnosed hepatic steatosis, the average hepatic fat content in our subjects was much higher than the general population, so further studies are needed to determine the clinical value of FGF21 as a biomarker for NAFLD in the general population. The gene discussed is FGF21; the disease is fatty liver disease.